Reversal of HIV-1-associated osteoporosis with once-weekly alendronate

Negredo, Eugeniaa; Martínez-López, Evab; Paredes, Rogera; Rosales, Joaquime; Pérez-Álvarez, Núriaa; Holgado, Susanac; Gel, Silviaa; Rio, Luís dele; Tena, Xavierc; Rey-Joly, Celestinod; Clotet, Bonaventuraa

AIDS:
Research Letters
Abstract

HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14). At week 96, 27% of patients on alendronate versus 96% of controls presented with osteoporosis. Spine bone mineral density (BMD) increases were detected at week 48, and progressed thereafter. Improvements in trochanter BMD were obtained after 2 years. Once-weekly oral alendronate may be an effective and safe treatment for HIV-1-associated osteoporosis.

Author Information

aLluita contra la SIDA Foundation

bClinical Nutrition Unit

cRheumatology

dInternal Medicine, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain

eCETIR Centre Mèdic, Barcelona, Spain.

Received 21 September, 2004

Accepted 3 November, 2004

© 2005 Lippincott Williams & Wilkins, Inc.